Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)

Inclusion Criteria: Biopsy proved treatment-naïve AL amyloidosis Fluorescence in situ hybridization (FISH) t(11;14) ≥ 10% dFLC > 50mg/L Exclusion Criteria: Co-morbidity of uncontrolled infection Co-morbidity of other active malignancy Co-diagnosis of multiple myeloma or waldenstrom macroglobulinemia Co-morbidity of grade 2 Mobitz II or grade 3 atrioventricular block (expect for those with implanted pacemaker) Co-morbidity of sustained or recurrent nonsustained ventricular tachycardia Seropositive for human immunodeficiency virus Hepatitis B virus (HBV)-DNA > 1000 copies/mL Seropositive for hepatitis C (except in the setting of a sustained virologic response) Systemic treatment with moderate or strong cytochrome P450 3A （CYP3A） inducers, moderate or strong CYP3A inhibitors within 7 days prior to the first dose of study drug Neutrophil <1×10E9/L，hemoglobin < 8g/dL，or platelet < 100×10E9/L. Severely compromised hepatic or renal function: alanine transaminase (ALT) or aspertate aminotransferase (AST) > 2.5 × upper limit of normal (ULN), total bilirubin > 3 × ULN，eGFR < 15 mL/min, or receiving renal replacement therapy